The Pathology of Transgenic Mice
Robert D. Cardiff, M.D., Ph.D.
Professor of Pathology and Medical Informatics
Department of Pathology
School of Medicine
University of California, Davis
This is a collection of slides and legends that constitute a brief
summary of the major aspects of transgenic mammary gland pathology. Click
on the underlined text to view the images and text for each subject matter.
This collection was used to deliver a presentation at the University of
Colorado, School of Medicine Cancer Center, Denver Colorado.
INDEX
1. Introduction and Outline.
2. Archives at the University of California, Davis
Transgenic Pathology Laboratory.
3. Normal growth and development of the mouse mammary
gland.
4. Comparison between breast lesions from human and
transgenic mouse.
5. Classification of transgenic tumors.
6. Neoplastic progression in PyV-MT transgenic tumors.
7. Angiogenesis in transgenic mammary tumors.
8. Last Reminder.
1. Introduction and Outline.
Text.
Back to Index
2. TheArchives
at the University of California, Davis Transgenic Pathology Laboratory
Text.
Back to Index
2. The Normal
Growth and development of the mouse mammary gland.
Text.
Back to Index
4. The comparison
between breast lesions from human and transgenic mouse.
Can you identify which is the mouse and which is the human?
Text.
Back to Index
5. The classification
of transgenic tumors.
The mammary tumors in transgenic mice are unique. Each transgene is associated
with a different identifiable type of tumor.
Text.
Back to Index
Almost 80% of all mouse mammary tumors metastasize. Some transgenic lines
have a very high rate of metastasis. The animals with the Polyoma Virus
Middle T transgene form tumors and have pulmonary metastases within 6 weeks
of birth.
Text.
Back to Index
7. Angiogenesis
in transgenic mammary tumors.
Transplants of PyV-MT tumors result in very angiogenic tumors. The complexity
of the microcirculation correlates to the ability to metastasize.
Text.
Back to Index
Text.
Back to Index
Click
here to go to the bibliography.
LAST ENTERED March 31, 1997
